anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to stasis eliminating powder for treating soft tissue injury and cervical spondylosis. The stasis eliminating powder is prepared from the following raw material drugs in parts by weight: 1150 to 1350 parts of dandelion, 400 to 600 parts of rhubarb, 400 to 600 parts of myrrh, 400 to 600 parts of pseudo-ginseng, 400 to 600 parts of Chinese polyphaga, and 725 to 925 parts of geranium wilfordii. The invention also provides application of the stasis eliminating powder. The stasis eliminating powder has the advantages that: the stasis eliminating power is compatible with a principle of Chinese medicament 'monarch, minister, assistant and guide', and has the remarkable effects of dissipating blood stasis to promote menstruation, and alleviating pain and removing stagnation. The stasis eliminating powder is suitable for treating pains, swelling and inflammations caused by cervical spondylosis, osteoarthritis, lumbar muscle strain, lumbar disc herniation, rheumatoid arthritis, hyperosteogeny, gout and scapulohumeral periarthritis, and also can be used for treating symptoms of traumatic injuries, blood stasis, undispersed abdominal stasis and joint stasis. The stasis eliminating powder has less toxic and side effects and good curative effect, contains few medicaments and is suitable for long-term administration, and thus the stasis eliminating powder is a safe and effective medicament.
Severe liver injury, including fatal liver failure, has been reported in some patients treated with leflunomide. Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) of greater than twice the upper limits of normal (>2xULN) before initiating treatment, should not be treated with leflunomide. Use caution when leflunomide is given with other potentially hepatotoxic drugs. Monitoring of ALT levels is recommended at least monthly for six months after starting leflunomide, and thereafter every 6 to 8 weeks. If ALT elevation > 3 fold ULN occurs, interrupt leflunomide therapy and investigate the cause. If likely leflunomide-induced, perform the accelerated drug elimination procedure and monitor liver tests weekly until normalized [see Warnings and Precautions ( 5.3)] . If leflunomide-induced liver injury is unlikely because some other cause has been found, resumption of leflunomide therapy may be considered. If leflunomide and methotrexate are given concomitantly, follow the American College of Rheumatology (ACR) guidelines for monitoring methotrexate liver toxicity with ALT, AST, and serum albumin testing.
The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as "President AB powder", which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan).
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as restoration of immune response to HBV. Direct-acting antivirals targeting virus entry, capsid assembly, viral protein production and secretion are in clinical trials. In parallel, immune modulatory therapies to stimulate HBV-specific immune response and to remove immune blockade are being tested. Clinical trials of direct-acting antivirals alone or immune modulatory therapies alone have not been successful in achieving HBV cure. Recent combinations of direct-acting antivirals and immune modulatory therapies have shown promising results particularly with combinations that included pegIFN-α. These results need to be confirmed in larger studies with longer follow-up, and further work is needed to develop simpler regimens with fewer drugs that can be administered orally and safely. While there is a strong desire to develop finite therapies that can achieve HBV cure, safety is paramount and new therapies must provide incremental value compared to standard of care, which is predominantly long-term NA therapy.
BACKGROUND: Multiquadrant procedures are technically more demanding than sequential operations. The new single port (SP) system allows to work in every abdominal quadrant maintaining an adequate triangulation without the need for changes in the port positioning.
METHODS: In February 2020, two patients underwent a robotic SP partial nephrectomy for malignancy combined with a cholecystectomy and a left inguinal hernia repair respectively.
RESULTS: Both procedures were successfully completed with one robotic docking and without the need for conversion. The operative time was 213 minutes for the right partial nephrectomy (126 min) with cholecystectomy (18 min), and 257 minutes for the left partial nephrectomy (161 min) with inguinal hernia repair (35 min). Estimated blood loss was 200 (150-250) mL, while the total warm ischemia time was 15 minutes for the right partial nephrectomy and 53 minutes for the left partial nephrectomy. There were no intraoperative complications or perioperative transfusions. The postoperative course was uneventful, and the postoperative hospital stay was 1 and 2 days. Both resections had free margins and the median tumor size was 2.5 (1.5-3.5) cm. Histopathology analysis revealed chronic cholecystitis and renal cell carcinomas with free margins and a median tumor size of 2.5 (1.5-3.5) cm. After a mean follow-up of 24 months, no surgical-related complications or recurrence were detected.
CONCLUSIONS: The robotic SP approach facilitates the completion of combined surgical procedures in multiple abdominal quadrants through a single 25mm incision.
Diabetic kidney disease (DKD), a chronic kidney disease, is characterized by progressive fibrosis caused due to persistent hyperglycemia. The development of fibrosis in DKD determines the patient prognosis, but no particularly effective treatment. Here, small extracellular vesicles derived from mesenchymal stem cells (MSC-sEV) have been used to treat DKD fibrosis. Single-cell RNA sequencing was used to analyze 27,424 cells of the kidney, we have found that a novel fibrosis-associated TGF-β1+Arg1+ macrophage subpopulation, which expanded and polarized in DKD and was noted to be profibrogenic. Additionally, Actin+Col4a5+ mesangial cells in DKD differentiated into myofibroblasts. Multilineage ligand-receptor and cell-communication analysis showed that fibrosis-associated macrophages activated the TGF-β1/Smad2/3/YAP signal axis, which promotes mesangial fibrosis-like change and accelerates renal fibrosis niche. Subsequently, the transcriptome sequencing and LC-MS/MS analysis indicated that MSC-sEV intervention could restore the levels of the kinase ubiquitin system in DKD and attenuate renal interstitial fibrosis via delivering CK1δ/β-TRCP to mediate YAP ubiquitination degradation in mesangial cells. Our findings demonstrate the unique cellular and molecular mechanisms of MSC-sEV in treating the DKD fibrosis niche at a single-cell level and provide a novel therapeutic strategy for renal fibrosis.
ETHNOPHARMACOLOGICAL RELEVANCE: Natural products have emerged as a novel source in the management of non-communicable diseases, more so in diabetes mellitus and its comorbidities. Aloe vera is widely recognized for its anti-hyperglycemic and anti-hyperlipidemic properties and numerous researchers have identified component (s) from Aloe vera attributing to these therapeutic effects.
AIM OF THE STUDY: The current work was undertaken to gain insight into the protective effect of Aloe vera (L.) Burm. f. extract to study the cytoarchitecture/histopathological alterations in the target organs in mutant Obese WNIN/GR-Ob rats that were made frank diabetic with streptozotocin.
MATERIALS AND METHODS: Rats were divided into five groups. 1)WNIN-GR-Ob/control group 2)WNIN-GR-Ob treated with STZ 3)WNIN-GR-Ob + STZ + Sitagliptin 4)WNIN-GR-Ob + STZ + Aloe vera 5)WNIN-GR-Ob/control group + Aloe vera. Histopathological analysis of the pancreas, kidney, liver, and adipocytes was done after 4 weeks of treatment.
RESULTS: The histopathological examination of STZ-induced diabetic rats revealed significant changes in all the vital organs including cell infiltration, degeneration, and necrosis. Treatment with A. vera negated most of the histopathological changes seen in STZ induced rats. Sitagliptin-which served as a positive control in the present study-reversed the alterations seen in streptozotocin rats.
CONCLUSION: Considering the hypoglycaemic and hypolipidemic activities of Aloe vera that have been previously demonstrated by us, the present study further re-instates the therapeutic efficacy of Aloe vera towards vital organs. It was able to restore islet cells and reduce β-cell damage. In addition, it was also able to aid in kidney tubular regeneration and reverse the degenerative changes brought on by streptozotocin on liver. Further, Aloe vera treated group exhibited moderate hyperplasia with decreased size of adipocytes and reduced macrophage infiltration. Thus, our findings advocate its application as an important nutraceutical in the therapeutic management of diabetes mellitus and associated complications.
PURPOSE:To establish the titled cell strain useful for test to confirm reactivity of basophilic cells playing a important role in allergic reactions, etc., or development of a remedy or diagnostic agent for diseases caused by immunological reactions, e.g. allergy, etc., from human monocytes. CONSTITUTION:Human monocytes, e.g. monocytes of human cord blood or monocytes of peripheral blood of patients with allergic diseases, are stimulated with IgE antibody or dead Staphylococcus aureus and human interleukin (IL)-3- like factor is added and cultivated. The above-mentioned cultivation is repeated to isolate and cultivate a clone capable of cultivating for a long period. The clone is then activated with antiIgE antibody, etc., to afford a cell strain reactive with the human IL-3-like factor. The established cells are relatively large- sized and the clone has large and small granules exhibiting different staining denaturation and hold IgE receptor, but no IgE-antiIgE antibody reaction or remarkable release of histamine in calcium ionophore are recognized.
The invention relates to a flukanide transdermal solution used for treating parasitic diseases of cattle and sheep, and a preparation method thereof. The flukanide transdermal solution comprises, by volume, 5 to 15 parts of acetone, 3 to 5 parts of ethyl acetate, 15 to 20 parts of dimethyl sulfoxide, 2 to 6 parts of azone, 1 to 3 parts of isopropanol, and 50 to 70 parts of propylene glycol. Each 100ml of the flukanide transdermal solution comprises 1 to 3g of flukanide. The flukanide transdermal solution is prepared via dissolving, mixing, filtering, and filling. According to the flukanide transdermal solution, azone is a novel skin penetration promoter, is capable of promoting transdermic absorption of skin on a plurality of types of medicines, avoiding liver first pass effects effectively and generation of peak valley phenomenon in medicine absorption processes, reducing toxic and side effects caused by medicine or dosage factors, prolonging effective acting time, changing drug administration area, adjusting administration dosage effectively, and reducing inter-individual difference. The flukanide transdermal solution is simple, convenient, and fast for using, and is more suitable for prevention of parasite in pastoral areas than other dosage forms.
The safety and effectiveness of sulfasalazine delayed release tablets in pediatric patients below the age of 2 years with ulcerative colitis have not been established.

The safety and effectiveness of sulfasalazine delayed release tablets for the treatment of the signs and symptoms of polyarticular-course juvenile rheumatoid arthritis in pediatric patients aged 6–16 years is supported by evidence from adequate and well-controlled studies in adult rheumatoid arthritis patients. The extrapolation from adults with rheumatoid arthritis to children with polyarticular-course juvenile rheumatoid arthritis is based on similarities in disease and response to therapy between these two patient populations. Published studies support the extrapolation of safety and effectiveness for sulfasalazine to polyarticular-course juvenile rheumatoid arthritis1,5 (see ADVERSE REACTIONS).

It has been reported that the frequency of adverse events in patients with systemic-course of juvenile arthritis is high.6 Use in children with systemic-course juvenile rheumatoid arthritis has frequently resulted in a serum sickness-like reaction.5 This reaction is often severe and presents as fever, nausea, vomiting, headache, rash, and abnormal liver function tests. Treatment of systemic-course juvenile rheumatoid arthritis with sulfasalazine is not recommended.
PURPOSE: We aimed to assess whether the presence of contaminants in the pre-operative urine culture (preop-UC) predicts postoperative urinary tract infection (postop-UTI) in patients undergoing elective ureteroscopy with laser lithotripsy.
METHODS: A retrospective chart review was performed from 01/2019 to 12/2021 examining patients with unilateral stone burden ≤ 2 cm who underwent ureteroscopy with laser lithotripsy and had a preop-UC within 3 months. Positive, negative, contaminated, and polymicrobial definitions for UCs were established in accordance with current guidelines. Patients with positive and polymicrobial cultures were excluded. Postop-UTI was defined as the presence of urinary symptoms and a positive UC within 30 days of the procedure. Multivariable logistic regression models were utilized to evaluate risk factors for contamination in the preop-UC and the risk of postop-UTI.
RESULTS: A total of 201 patients met the inclusion-exclusion criteria. Preop-UC was negative in 153 patients and contaminated in 48 patients. Significant contaminant-related factors included female gender and increased BMI. Postop-UTI was diagnosed in 3.2% of patients with negative preop-UCs and 4.2% of patients with contaminants, with no difference between groups (p = 0.67). The regression model determined that the presence of contaminants in preop-UC failed to predict postop-UTI (OR 0.69, p = 0.64).
CONCLUSION: The presence of contaminants in preop-UCs is not associated with an increased risk of postop-UTIs after ureteroscopy. Our study supports that contaminants in the preop-UC can be interpreted as a negative UC in terms of postop-UTI risk stratification. Preoperative antibiotics should not be prescribed for patients undergoing uncomplicated ureteroscopy for stone surgery in the setting of a contaminated preop-UC.
Participants in food effect assessment will receive M4076 at the dose and schedule determined as recommended dose for expansion (RDE) in Part 1A. A single dose of M4076 will be administered on Day -7 under a fed or fasted condition, followed by a 1-week washout period.
An expandable breast implant eliminates the need for multiple procedures and injections and is also capable of self-administered or automatic expansion that is safe in any environment. The expandable breast implant design includes an upper matrix, a lower matrix, and a middle layer. The upper matrix comprises a plurality of cells containing a first reagent. The lower matrix comprises a plurality of wells containing a second reagent. The middle layer acts as a barrier between the upper matrix and the lower matrix. The middle layer may be activated and controlled to form openings. The first reagent from the cells in the upper matrix mixes with the second reagent from the wells in the lower matrix through the selected openings in the middle layer. The reagents react to form a gas that permeates through a hydrophobic membrane into an expandable shell to enlarge the breast implant.
Rosacea and autoimmune liver diseases (AILDs) are diseases closely associated with immune system abnormalities. AILDs primarily includes autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Currently, research on the association between these two conditions is limited. Therefore, this study employed the bidirectional Mendelian randomization (MR) method to investigate potential causal relationships between rosacea and AILDs based on genetic predictions. Summary data related to Rosacea, AIH, PSC, and PBC were obtained from public genome-wide association studies (GWAS). The inverse variance weighted (IVW) method was used as the primary analytical approach, supplemented by the MR-Egger, weighted mode method, weighted median, and simple mode. A series of sensitivity analyses were also conducted to identify heterogeneity and pleiotropy effects. The MR analysis results indicated a significant increase in the risk of rosacea being associated with PBC (OR = 1.09, 95% CI = 1.02-1.18, P = 0.014), but no such association was found with AIH or PSC. Furthermore, this study did not find a significant impact of rosacea on the risk of AILDs. This study represents the first in-depth exploration of the potential causal relationship between rosacea and AILDs using MR analysis. Thes findings suggest an increased risk of rosacea among PBC patients.
INTRODUCTION: Genicular nerve blocks (GNBs) are an emerging technique that have been used as a part of multimodal analgesia for total knee arthroplasty. The efficacy of intraoperative landmark-based GNBs, a recently introduced technique, has been established. We hypothesized that it would provide non-inferior postoperative analgesia compared with periarticular infiltration (PAI) when combined with continuous adductor canal block.
METHODS: This study randomized 140 patients undergoing total knee arthroplasty to receive either intraoperative landmark-based GNB (GNB group) or PAI (PAI group), with 139 completing the study. The primary outcomes were the pain scores at rest and during movement at 12 hours postoperatively on an 11-point Numerical Rating Scale; the non-inferiority margin was 1. Pain scores at additional time points, intravenous morphine consumption, time to first rescue analgesia, functional performance and muscle strength tests, and sleep disturbance were also assessed.
RESULTS: At 12 hours postoperatively, the PAI and GNB groups had median resting pain scores of 0 (0-2) and 0 (0-2), respectively. The median difference was 0 (95% CI -0.4 to 0.4, p=1), with the 95% CI upper limit below the prespecified non-inferiority margin. The median pain score during movement was 1.5 (0-2.3) and 2 (1-3.1) in the PAI and GNB groups, respectively. The median difference was 0.9 (95% CI 0.3 to 1.6, p=0.004), failing to demonstrate non-inferiority. The GNB group had higher intravenous morphine consumption at 12 hours postoperatively and a shorter time to first rescue analgesia.
CONCLUSIONS: GNB compared with PAI provides non-inferior resting pain relief. Non-inferiority was not established for pain during movement.
TRIAL REGISTRATION NUMBER: TCTR20220406001 (www.thaiclinicaltrials.org).
Diabetic retinopathy (DR) is a diabetes-associated complication that poses a threat to vision, distinguished by persistent and mild inflammation of the retinal microvasculature. The activation of microglia plays a crucial role in driving this pathological progression. Previous investigations have demonstrated that ubiquitin-specific peptidase 25 (USP25), a deubiquitinating enzyme, is involved in the regulation of immune cell activity. Nevertheless, the precise mechanisms through which USP25 contributes to the development of DR remain incompletely elucidated. Firstly, we have demonstrated the potential mechanism by which ROCKs can facilitate microglial activation and augment the synthesis of inflammatory mediators through the modulation of NF-κB signaling pathways in a high-glucose milieu. Furthermore, our study has provided novel insights by demonstrating that the regulatory role of USP25 in the secretion of proinflammatory factors is mediated through the involvement of ROCK in modulating the expression of NF-κB and facilitating the nuclear translocation of the phosphatase NF-κB. This regulatory mechanism plays a crucial role in modulating the activation of microglial cells within a high-glycemic environment. Hence, USP25 emerges as a pivotal determinant for the inflammatory activation of microglial cells, and its inhibition exhibits a dual effect of promoting retinal neuron survival while suppressing the inflammatory response in the retina. In conclusion, the promotion of diabetic retinopathy (DR) progression by USP25 is attributed to its facilitation of microglial activation induced by high glucose levels, a process mediated by the ROCK pathway. These findings highlight the importance of considering USP25 as a potential therapeutic target for the management of diabetic neuroinflammation.
A 3(2H)-pyridazinone derivative of formula (I), its salt, a process for its production and a pharmaceutical composition containing it, wherein each of R?1, R2 and R3¿ which are independent of one another, is a hydrogen atom or a C¿1-4? alkyl group, X is a chlorine atom or a bromine atom, Y?1¿ is a hydrogen atom, a halogen atom, a nitro group, an amino group or a C¿1-4? alkoxy group, Y?2¿ is a hydrogen atom, a halogen atom, a hydroxyl group, a C¿1-4? alkyl group or a C1-4 alkoxy group, A is a C1-5 alkylene chain which may be substituted by a hydroxyl group, B is a carbonyl group or a methylene chain which may be substitued by a C1-4 alkyl group, and each of R?4 and R5¿ which are independent of each other, is a C¿1-4? alkyl group, or R?4¿ is a hydrogen atom and R5 is -Z-Ar (wherein Z is a C¿1-5? alkylene chain, and Ar is an aromatic 6-membered ring which may contain a nitrogen atom), or R?4 and R5¿ together form a C¿2-6? cyclic alkylene group, or R?4 and R5¿ form together with the adjacent nitrogen atom a 4-substituted piperazine ring of formula (a), wherein R6 is a C¿1-4? alkyl group.
Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
<P>PROBLEM TO BE SOLVED: To obtain a lipoic acid-containing complex which is a complex for simply preparing an α-lipoic acid emulsified or solubilized composition having excellent dispersion stability by using a phospholipid and in which the α-lipoic acid is stable in the complex.  <P>SOLUTION: The complex is obtained by removing an organic solvent from a solution in which (A) a phospholipid, (B) an α-lipoic acid and (C) an antioxidant are uniformly dissolved in the organic solvent so as to simultaneously precipitate the components (A)-(C). The complex is obtained by removing an organic solvent from a solution in which (A) a phospholipid, (B) an α-lipoic acid, (C) an antioxidant and (D) a sterol are uniformly dissolved in the organic solvent so as to simultaneously precipitate the components (A)-(D). The α-lipoic acid emulsified or solubilized composition using a phospholipid is simply prepared by using the complex. The obtained emulsified or solubilized composition has excellent dispersion stability. The α-lipoic acid is stable in the complex.  <P>COPYRIGHT: (C)2008,JPO&INPIT